摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one | 335077-70-8

中文名称
——
中文别名
——
英文名称
5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
英文别名
5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;5-(5-acetyl-2-butoxypyridin-3-yl)-3-ethyl-2-(1-ethylazetidin-3-yl)-6H-pyrazolo[4,3-d]pyrimidin-7-one
5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one化学式
CAS
335077-70-8
化学式
C23H30N6O3
mdl
——
分子量
438.53
InChiKey
INLBUQIADGPECI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    32
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    102
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one盐酸 作用下, 以 1,3-二噁烷乙酸乙酯 为溶剂, 反应 0.17h, 以81%的产率得到5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]-pyrimidin-7-one hydrochloride
    参考文献:
    名称:
    Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
    摘要:
    提供一种用于制备式(I)化合物的方法,包括在-OR3和氢氧化物捕获剂的存在下,反应式(II)、(III)、(IV)或(V)化合物,或者在辅助碱和氢氧化物捕获剂的存在下反应式(IV)化合物(即-OR3被辅助碱取代),其中X是离去基团,R1至R4如所定义。
    公开号:
    EP1176147A1
  • 作为产物:
    描述:
    5-ethyl-1-(1-ethyl-3-azetidinyl)-4-nitro-1H-pyrazole-3-carboxamide 在 palladium on activated charcoal 4 A molecular sieve 、 氢气caesium carbonateN,N'-羰基二咪唑 作用下, 以 乙醇乙酸乙酯 为溶剂, 20.0 ℃ 、413.68 kPa 条件下, 反应 25.5h, 生成 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
    参考文献:
    名称:
    A Novel Series of Potent and Selective PDE5 Inhibitors with Potential for High and Dose-Independent Oral Bioavailability
    摘要:
    Sildenafil ( 5-[ 2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl) phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[ 4,3-d] pyrimidin-7-one), a potent and selective phosphodiesterase type 5 ( PDE5) inhibitor, provided the first oral treatment for male erectile dysfunction. The objective of the work reported in this paper was to combine high levels of PDE5 potency and selectivity with high and dose-independent oral bioavailability, to minimize the impact on the C-max of any interactions with coadministered drugs in the clinic. This goal was achieved through identification of a lower clearance series with a high absorption profile, by replacing the 5'-piperazine sulfonamide in the sildenafil template with a 5'-methyl ketone. This novel series provided compounds with low metabolism in human hepatocytes, excellent caco-2 flux, and the potential for good aqueous solubility. The in vivo oral and iv pharmacokinetic profiles of example compounds confirmed the high oral bioavailability predicted from these in vitro screens. 5-( 5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-( 1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[ 4,3-d] pyrimidin-7-one ( 2) was selected for progression into the clinic.
    DOI:
    10.1021/jm060113e
点击查看最新优质反应信息

文献信息

  • Chemical Compounds
    申请人:Brown Alan Daniel
    公开号:US20120010182A1
    公开(公告)日:2012-01-12
    The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z 1 , R a , R b , R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
    该发明涉及磺胺衍生物,其在医学上的应用,含有它们的组合物,其制备方法以及用于这些方法的中间体。 更具体地,该发明涉及公式(I)的新磺胺基Nav1.7抑制剂: 或其药学上可接受的盐,其中Z 1 ,R a ,R b ,R 1 ,R 2 ,R 3 ,R 4 和R 5 如描述中所定义。 Nav 1.7抑制剂在治疗各种疾病,特别是疼痛方面具有潜在用途。
  • Substituted triazole derivatives as oxytocin antagonists
    申请人:Brown Daniel Alan
    公开号:US20060160786A1
    公开(公告)日:2006-07-20
    The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction.
    本发明涉及公式(I)的取代三唑化合物,其用途,制备方法以及含有该化合物的组合物。这些抑制剂在包括性功能障碍在内的各种治疗领域具有用途。
  • PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
    申请人:Hadida Ruah Sara Sabina
    公开号:US20120196869A1
    公开(公告)日:2012-08-02
    The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    这项发明涉及对离子通道具有抑制作用的吡咯吡嘧啶-螺环哌啶酰胺化合物。该发明还提供了包括该发明化合物的药学上可接受的组合物,以及使用这些组合物治疗各种疾病的方法。
  • [EN] PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE EN TANT QUE BLOQUANTS DE TTX-S
    申请人:RAQUALIA PHARMA INC
    公开号:WO2014068988A1
    公开(公告)日:2014-05-08
    The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及吡唑并吡啶衍生物,这些衍生物具有阻断TTX-S型电压门控钠通道的活性,并且在治疗或预防涉及电压门控钠通道的疾病和障碍中是有用的。该发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
  • [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
    申请人:PFIZER LTD
    公开号:WO2009144632A1
    公开(公告)日:2009-12-03
    The present invention relates to a class of substituted purine compounds of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These compounds have utility in a variety of therapeutic areas including sexual dysfunction.(I).
    本发明涉及一类取代嘌呤化合物的公式(I),其用途、制备过程以及包含所述化合物的组合物。这些化合物在包括性功能障碍在内的多种治疗领域具有用途。
查看更多